ZZ Biotech begins Phase 1 clinical study to treat acute ischemic stroke

By Admin
Houston-based ZZ Biotech, LLC has initiated a Phase 1 clinical study with 3K3A-APC to treat acute ischemic stroke. The Phase 1 study is a randomized, d...

Houston-based ZZ Biotech, LLC has initiated a Phase 1 clinical study with 3K3A-APC to treat acute ischemic stroke.

The Phase 1 study is a randomized, double-blind, placebo-controlled, single-center trial that will investigate the safety and pharmacokinetics of single and multiple ascending doses of 3K3A-APC in healthy adult volunteers, the news reports said.

About 62 adults subjects will be assigned sequentially to 1 of 10 cohorts, at successively higher single doses, followed by successively higher multiple doses.

The results of the study are expected in the first quarter of 2013.

“We are very pleased to have received the approval from the Austrian Agency for Health and Food Safety to initiate our first human study with 3K3A-APC,” said, Dr. Kent Pryor, Chief Operating Officer of ZZ Biotech. Mr. Pryor also said, “Our extensive preclinical studies into the neuroprotective effects of 3K3A-APC suggest that it is a promising candidate for the treatment of ischemic stroke.”

ZZ Biotech is a company based in Houston, TC. It develops innovative biological treatments for the aging and damaged brain, including those affected by stroke and other neurodegenerative disorders. 3K3A-APC is a genetically engineered variant of the naturally occurring activated protein C (APC) which plays a role in regulation of inflammation and blood clotting.
 

Share
Share

Featured Articles

London, Paris & Cambridge 'Healthcare Finance Capitals'

Pitchbook report shows London, Paris and UK's Cambridge dominated investment in healthcare in Q1 2024, with Israel also bouyant

Philips Future Health Index Report: AI to Cut Waiting Times

Healthcare technology leader Philips says virtual care and AI is turning in an effort to cope with demand in its Future Health Index Report 2024

HCLTech and Olympus Advance AI into the Healthcare Industry

Giants HCLTech and Olympus Corporation, have developed their partnership to utilise technology and AI to transform the healthcare industry.

Cancer Vaccines Breakthrough a Glimpse of Healthcare Future

Medical Devices & Pharma

Change Healthcare Cyberattack Fallout Continues

Health Insurance & Finance

McKinsey: National E-health Initiatives on the Rise

Technology & AI